How Does CBD Make You Feel? Reading the Evidence

So what are you actually noticing?

Ask ten people and you get ten answers. That isn't a dodge. It's the honest starting point, and there's published work behind it.

Colloca and Barsky reviewed placebo and nocebo effects in 2020. Their description of what a person registers after taking any substance has two parts: the pharmacology of the substance, and the anticipation carried in before intake [1]. Both parts land in the report afterwards. Only one of them came out of the bottle.

In a blinded trial, the design holds those two apart. Nobody knows who received what, so the difference between the groups can be assigned to the substance. Outside that setup, on an ordinary Tuesday evening in an ordinary kitchen, the two contributions sit almost on top of each other and are near-inseparable [1]. It's why the question of how much of a cannabidiol response is a placebo response keeps being discussed in the literature rather than closed [1].

Expectation is not a footnote in this. What someone anticipates before intake makes a measurable contribution to what they report later [1]. Worth rereading if you've ever judged a product on a single evening.

• The pharmacology of what was taken, meaning how much reached the bloodstream, how fast, and for how long.
• The anticipation held before intake, which contributes measurably to the account that follows [1].
• A blinded design, which exists precisely to keep those two contributions apart [1].
• Everyday use, where no blinding exists and the two contributions cannot be told apart [1].
• The open discussion in the research, which asks how far cannabidiol responses overlap with placebo responses [1].

Why THC vocabulary doesn't carry over

Underneath the question, there's usually a second one. Will this get me high?

A receptor is a docking point on a cell. An agonist is a molecule that docks there and switches the signal on. Cannabidiol is not a classical agonist at cannabinoid receptor type 1, generally shortened to CB1, and that CB1 route is the documented interaction behind THC intoxication.

Huestis published a review of human cannabinoid pharmacokinetics in 2007. It covers the absorption, distribution and metabolism of THC alongside the receptor pharmacology of that intoxicating profile [2]. Cannabidiol does not share the same binding profile, so the descriptors written for THC are not transferable to it.

That settles one thing and one thing only. Our products sit within the legal THC limits and are non-intoxicating, and we say that plainly rather than dressing it up. What the receptor evidence does not do is predict what any individual will notice on a given afternoon. Different question, different kind of data.

• CB1: the receptor route documented in connection with THC intoxication [2].
• Cannabidiol: not a classical agonist at that receptor.
• The 2007 Huestis review: absorption, distribution, metabolism and receptor pharmacology of the intoxicating profile [2].
• The binding profile is not shared, which is why THC language cannot be borrowed for cannabidiol.
• What stays open: the receptor point answers the intoxication question, not the personal-experience one.

Dose, route, food, clock

Pharmacokinetics is a long word for a plain idea: what happens to a compound after intake. How much of it gets into circulation, how quickly it gets there, and how long it stays.

Millar and colleagues published a systematic review of cannabidiol pharmacokinetics in humans in 2018. The finding that runs through it is variability. Wide variability across the studies reviewed, with human exposure shaped by the dose, the route of administration, and whether food was taken alongside [3]. That variability is not a gap in the record. It is the record.

Four variables do most of the work, and each one is documented separately.

• Dose. Blood concentrations differ according to the amount administered. What has not been established is a consistent relationship between a given amount and a given subjective state [3].
• Route. Oral, oromucosal and inhaled administration produce differing concentrations and differing times to peak across the human studies reviewed [3].
• Food. Oral exposure is variable, and taking a dose with food differs from taking it without [3].
• Timing. Time to peak depends on the route, so the same amount looked at twenty minutes after intake and three hours after intake is not the same exposure [3].
• Expectation. Sitting across all four, the anticipation held before intake adds its own measurable contribution to the report [1].

Five notes from the human record

1. Iffland and Grotenhermen set out the reported safety profile of cannabidiol in human research in their 2017 review. Among the effects noted at the doses studied are tiredness and changes in appetite [4]. That is the level of specificity the record supports, and it's worth taking it at that level.
2. Two features of that record deserve attention. The first: reported effects come from specific study populations. What a defined group of participants reported under trial conditions is a description of that group under those conditions.
3. The second: the doses studied are frequently far above the amounts a general consumer takes. A figure recorded at a research dose cannot be read across to a few drops from a pipette bottle.
4. Which is why the published record is not a preview of what a particular reader will notice [1]. It is an account of what was measured, in named populations, at stated amounts.
5. The pharmacokinetic side stays open in the same way. Millar's 2018 review reports wide variability in human exposure, and exposure is the thing that was measured, not experience [3]. Between those two sits everything this page cannot tell you.

Worth writing down, once

1. The amount, in milligrams, read off the label. It's the one variable you can attach to a number, and blood concentrations do differ by amount administered [3].
2. The route. Oral, oromucosal or inhaled: each produced different concentrations and different times to peak in the human studies reviewed [3].
3. Whether you had eaten. Oral exposure varies with food and without it [3], so a note as short as "after breakfast" carries real information.
4. The clock. Time to peak is route-dependent, so noting the gap between intake and observation keeps two different exposures from being filed as one [3].
5. What you expected beforehand. Anticipation contributes measurably to the report that follows [1], and it's the part nobody else can record on your behalf.
6. How many observations you actually have. One evening is one observation. Colloca and Barsky's 2020 framing is that outside a blinded design the substance and the anticipation cannot be pulled apart [1].
7. Anything else you take. Questions about medication or an existing condition belong with a doctor or pharmacist, before anything else on this list.
8. What's in the bottle. Since 2014 the standard here has been the same: every batch independently analysed and the report published, so the milligram figure in note one is something you can check rather than assume.